How should we treat a patient with early Parkinson's disease?

International Journal of Clinical Practice

Volumn 64, Issue 9, 2010, Pages 1210-1219

  Tsouli, S ^a   Konitsiotis, S ^a  

^a UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

2BETA CARBOXYMETHOXY 3BETA [4 IODOPHENYL]TROPANE; 6 FLUORODOPA; AMANTADINE; BENSERAZIDE PLUS LEVODOPA; BROMOCRIPTINE; CARBIDOPA; CARBIDOPA PLUS ENTACAPONE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; DOMPERIDONE; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; LEVODOPA; MONOAMINE OXIDASE B INHIBITOR; MONOAMINE OXIDASE INHIBITOR; PERGOLIDE; PLACEBO; PRAMIPEXOLE; RASAGILINE; ROPINIROLE; ROTIGOTINE; SAFINAMIDE; SELEGILINE; TOCOPHEROL; TOLCAPONE; TROPANE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; BEHAVIOR CHANGE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; COGNITIVE DEFECT; DISEASE COURSE; DOPAMINERGIC NERVE CELL; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DYSKINESIA; DYSTONIA; ESSENTIAL TREMOR; FIBROSIS; FOOD DRUG INTERACTION; HUMAN; LIVER TOXICITY; LOW DRUG DOSE; MONOTHERAPY; MORNING DOSAGE; MORTALITY; NAUSEA; NEUROPROTECTION; NEUROTOXICITY; NIGRONEOSTRIATAL SYSTEM; ORTHOSTATIC HYPERTENSION; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PATHOLOGICAL GAMBLING; PERIPHERAL EDEMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SOMNOLENCE; TREATMENT OUTCOME; TREATMENT RESPONSE; UNIFIED PARKINSON DISEASE RATING SCALE; UNSPECIFIED SIDE EFFECT; VALVULAR HEART DISEASE; VOMITING;

ANTIPARKINSON AGENTS; CATECHOL O-METHYLTRANSFERASE; DOPAMINE AGONISTS; FOOD-DRUG INTERACTIONS; HUMANS; MONOAMINE OXIDASE INHIBITORS; PARKINSON DISEASE; PRACTICE GUIDELINES AS TOPIC;

EID: 77954650148     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2010.02371.x     Document Type: Review

References (103)

1. Nussbaum RL, Ellis CE. Alzheimer's disease and Parkinson's disease. N Engl J Med 2003 348 : 1356 1364.
2. Van Den Eeden SK, Tanner CM, Bernstein AL et al. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am J Epidemiol 2003 157 : 1015 1022.
3. Zhang ZX, Roman GC. Worldwide occurrence of Parkinson's disease: an updated review. Neuroepidemiology 1993 12 : 195 208.
4. de Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol 2006 5 : 525 535.
5. Siderowf AD, Holloway RG, Stern MB. Cost-effectiveness analysis in Parkinson's disease: determining the value of interventions. Mov Disord 2000 15 : 439 445.
6. Di Monte DA, McCormack A, Petzinger G et al. Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model. Mov Disord 2000 15 : 459 466.
7. Lang AE, Obeso JA. Time to move beyond nigrostriatal dopamine deficiency in Parkinson's disease. Ann Neurol 2004 55 : 761 765.
8. Calne DB. Treatment of Parkinson's disease. N Engl J Med 1993 329 : 1021 1027.
9. Levine CB, Fahrbach KR, Siderowf AD et al. Diagnosis and treatment of Parkinson's disease: a systematic review of the literature. Evid Rep Technol Assess 2003 57 : 1 306.
10. Katzenschlager R, Lees AJ. Treatment of Parkinson's disease: levodopa as the first choice. J Neurol 2002 249 : 19 24.
11. Katzenschlager R, Head J, Schrag A et al. Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. Neurology 2008 71 : 474 480.
12. Nutt JG, Fellman JH. Pharmacokinetics of levodopa. Clin Neuropharmacol 1984 7 : 35 49.
13. Fabbrini G, Mouradian MM, Juncos JL et al. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part I. Ann Neurol 1988 24 : 366 371.
14. Filion M. Physiologic basis of dyskinesia. Ann Neurol 2000 47 : 35 40.
15. Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001 16 : 448 458.
16. Sharma JC, Macnamara L, Hasoon M et al. Cascade of levodopa dose and weight-related dyskinesia in Parkinson's disease (LD-WD-PD cascade). Parkinsonism Relat Disord 2006 12 : 499 505.
17. Sharma JC, Ross IN, Rascol O et al. Relationship between weight, levodopa and dyskinesia: the significance of levodopa dose per kilogram body weight. Eur J Neurol 2008 15 : 493 496.
18. Olanow CW, Obeso JA, Stocchi F. Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol 2006 5 : 677 687.
19. Schapira AH, Olanow CW. Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions. JAMA 2004 291 : 358 364.
20. Michel PP, Hefti F. Toxicity of 6-hydroxydopamine and dopamine for dopaminergic neurons in culture. J Neurosci Res 1990 26 : 428 435.
21. Ziv I, Melamed E, Nardi N et al. Dopamine induces apoptosis-like cell death in cultured chick sympathetic neurons - a possible novel pathogenetic mechanism in Parkinson's disease. Neurosci Lett 1994 170 : 136 140.
22. Agid Y, Olanow CW, Mizuno Y. Levodopa: why the controversy? Lancet 2002 360 : 575.
23. Agid Y. Levodopa. Is toxicity a myth? Neurology 1998 50 : 858 863.
24. Fahn S the Parkinson Study Group. Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol 2005 252 : 37 42.
25. Mena MA, Davila V, Sulzer D. Neurotrophic effects of L-DOPA in postnatal midbrain dopamine neuron/cortical astrocyte cocultures. J Neurochem 1997 69 : 1398 1408.
26. Murer G, Dziewczapolski G, Menalled LB et al. Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions. Ann Neurol 1998 43 : 561 575.
27. Quinn N, Parkes D, Janota I et al. Preservation of the substantia nigra and locus coeruleus in a patient receiving levodopa (2 kg) plus decarboxylase inhibitor over a four-year period. Mov Disord 1986 1 : 65 8.
28. Rajput AH. The protective role of levodopa in the human substantia nigra. Adv Neurol 2001 86 : 327 336.
29. Fahn S, Oakes D, Shoulson I et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004 351 : 2498 2508.
30. Agid Y, Ahlskog E, Albanese A et al. Levodopa in the treatment of Parkinson's disease: a consensus meeting. Mov Disord 1999 14 : 911 913.
31. Ben-Shlomo Y, Marmot MG. Survival and cause of death in Parkinson's disease: possible clues to aetiology? J Neurol Neurosurg Psychiatry 1995 58 : 293 299.
32. Clarke CE. Does levodopa therapy delay death in Parkinson's disease? A review of the evidence. Mov Disord 1995 10 : 250 256.
33. Nutt JG, Woodward WR, Beckner RM et al. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 1994 44 : 913 919.
34. Parkinson Study Group. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Ann Neurol 1997 42 : 747 755.
35. Schrag A. Entacapone in the treatment of Parkinson's disease. Lancet Neurol 2005 4 : 366 370.
36. Olanow CW. Tolcapone and hepatotoxic effects: Tasmar Advisory Panel. Arch Neurol 2000 57 : 263 267.
37. Hausser R, Panisset G, Abbruzzese L et al. Improved symptom control with fixed dose levodopa/carvidopa/entacapone (LCE) versus conventional levodopa/carvidopa (LC) as first line levodopa therapy in early Parkinsons disease patients. Mov Disord 2008 23 : 208.
38. Smith LA, Jackson MJ, Al-Barghouthy G et al. Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates. Mov Disord 2005 20 : 306 314. (Pubitemid 40613291)
39. Goetz CG, Poewe W, Rascol O et al. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Mov Disord 2005 20 : 523 539.
40. Management of Parkinson's disease: an evidence-based review. Mov Disord 2002 17 : 1 166.
41. Kondo T. Initial therapy for Parkinson's disease: levodopa vs. dopamine receptor agonists. J Neurol 2002 249 : 25 9.
42. Watts RL. The role of dopamine agonists in early Parkinson's disease. Neurology 1997 49 : 34 48.
43. Le WD, Jankovic J. Are dopamine receptor agonists neuroprotective in Parkinson's disease? Drugs Aging 2001 18 : 389 396.
44. Sawada H, Ibi M, Kihara T et al. Dopamine D2-type agonists protect mesencephalic neurons from glutamate neurotoxicity: mechanisms of neuroprotective treatment against oxidative stress. Ann Neurol 1998 44 : 110 119.
45. Iida M, Miyazaki I, Tanaka K et al. Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist. Brain Res 1999 838 : 51 9.
46. Gomez-Vargas M, Nishibayashi S, Asanuma S et al. Pergolide scavenges both hydroxyl and nitric oxide free radicals in vitro and inhibits lipid peroxidation in different regions of the rat brain. Brain Res 1998 790 : 202 208.
47. Muralikrishnan D, Mohanakumar KP. Neuroprotection by bromocriptine against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice. FASEB J 1998 12 : 905 912.
48. Zou L, Jankovic J, Rowe DB et al. Neuroprotection by pramipexole against dopamine and levodopa-induced cytotoxicity. Life Sci 1999 64 : 1275 1285.
49. Schapira AH. Progress in neuroprotection in Parkinson's disease. Eur J Neurol 2008 15 : 5 13.
50. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs. levodopa on Parkinson disease progression. JAMA 2002 287 : 1653 1661.
51. Whone AL, Watts RL, Stoessl AJ et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REALPET study. Ann Neurol 2003 54 : 93 101.
52. Ahlskog JE. Slowing Parkinson's disease progression: recent dopamine agonist trials. Neurology 2003 60 : 381 389.
53. Ravina B, Eidelberg D, Ahlskog JE et al. The role of radiotracer imaging in Parkinson disease. Neurology 2005 64 : 208 215.
54. Avorn J, Schneeweiss S, Sudarsky LR et al. Sudden uncontrollable somnolence and medication use in Parkinson disease. Arch Neurol 2005 62 : 1242 1248.
55. Silver DE, Ruggieri S. Initiating therapy for Parkinson's disease. Neurology 1998 50 : 18 22.
56. Yamamoto M, Uesugi T, Nakayama T. Dopamine agonists and cardiac valvulopathy in Parkinson disease: a case-control study. Neurology 2006 67 : 1225 1229.
57. Zanettini R, Antonini A, Gatto G et al. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 2007 356 : 39 46.
58. Holloway RG, Shoulson I, Fahn S et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomised controlled trial. Arch Neurol 2004 61 : 1044 1053.
59. Rascol O, Brooks DJ, Korczyn AD et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med 2000 342 : 1484 1491.
60. Hauser RA, Rascol O, Korczyn AD et al. Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. Mov Disord 2007 22 : 2409 2417.
61. Constantinescu R, Romer M, McDermott MP et al. Impact of pramipexole on the onset of levodopa-related dyskinesias. Mov Disord 2007 22 : 1317 1319.
62. Matheson AJ, Spencer CM. Ropinirole: a review of its use in the management of Parkinson's disease. Drugs 2000 60 : 115 137.
63. Parkinson Study Group. A controlled trial of rotigotine monotherapy in early Parkinson's disease. Arch Neurol 2003 60 : 1721 1728.
64. Jenner P. A novel dopamine agonist for the transdermal treatment of Parkinson's disease. Neurology 2005 65 : 3 5.
65. Cawello W, Wolff HM, Meuling WJ, Horstmann R, Braun M. Transdermal administration of radiolabelled [14C]rotigotine by a patch formulation: a mass balance trial. Clin Pharmacokinet 2007 46 : 851 857.
66. Metman LV, Gillespie M, Farmer C et al. Continuous transdermal dopaminergic stimulation in advanced Parkinson's disease. Clin Neuropharmacol 2001 24 : 163 169.
67. Guldenpfennig WM, Poole KH, Sommerville KW et al. Safety, tolerability, and efficacy of continuous transdermal dopaminergic stimulation with rotigotine patch in early-stage idiopathic Parkinson disease. Clin Neuropharmacol 2005 28 : 106 110.
68. Watts RL, Jankovic J, Waters C et al. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology 2007 68 : 272 276. (Pubitemid 46148338)
69. Jankovic J, Watts RL, Martin W et al. Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease. Arch Neurol 2007 64 : 676 682. (Pubitemid 46789833)
70. Giladi N, Boroojerdi B, Korczyn AD et al. Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole. Mov Disord 2007 22 : 2398 2404.
71. Reynolds GP, Riederer P, Rausch WD. Dopamine metabolism in human brain: effect of monoamine oxidase inhibition in vitro by (-)deprenyl and (+) and (-) tranylcypromine. J Neural Transm 1980 16 : 173 178.
72. Knoll J. Deprenyl (selegiline): the history of its development and pharmacological action. Acta Neurol Scand 1983 95 : 57 80.
73. Youdim MBH, Gross A, Finberg JPM. Rasagiline [N-propargyl-1R(+)- aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br J Pharmacol 2001 132 : 500 506.
74. Youdim MB, Riederer PF. A review of the mechanisms and role of monoamine oxidase inhibitors in Parkinson's disease. Neurology 2004 63 : 32 5.
75. Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993 328 : 176 183.
76. Shoulson I, Oakes D, Fahn S et al. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomised placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann Neurol 2002 51 : 604 612.
77. Pålhagen S, Heinonen E, Hägglund J et al. Selegiline slows the progression of the symptoms of Parkinson disease. Neurology 2006 66 : 1200 1206.
78. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol 2002 59 : 1937 1943.
79. Rascol O. "Disease-modification" trials in Parkinson disease: target populations, endpoints and study design. Neurology 2009 72 : 51 8.
80. Bhattaram VA, Siddiqui O, Kapcala LP et al. Endpoints and analyses to discern disease-modifying drug effects in early Parkinson's disease. AAPS J 2009 11 : 456 464.
81. Leber P. Observations and suggestions on antidementia drug development. Alzheimer Dis Assoc Disord 1996 10 : 31 5.
82. Olanow CW, Rascol O, Hauser R et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 2009 361 : 1268 1278.
83. Olanow CW, Rascol O. Early Rasagiline Treatment Slows UPDRS Decline in the ADAGIO Delayed Start Study. Ann Neurol 2008 64 (S 12 68.
84. Onofrj M, Bonanni L, Thomas A. An expert opinion on safinamide in Parkinson's disease. Expert Opin Investig Drugs 2008 17 : 1115 1125.
85. Stocchi F, Arnold G, Onofrj M et al. Improvement of motor function in early Parkinson disease by safinamide. Neurology 2004 63 : 746 748.
86. Ives NJ, Stowe RL, Marro J et al. Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients. BMJ 2004 329 : 593.
87. Parkinson Study Group. Mortality in DATATOP: a multicenter trial in early Parkinson's disease. Ann Neurol 1998 43 : 318 325.
88. Fernandez HH, Chen JJ. Monoamine oxidase-B inhibition in the treatment of Parkinson's disease. Pharmacotherapy 2007 27 : 174 185.
89. Crosby N, Deane KHO, Clarke CE. Amantadine in Parkinson's disease (Cochrane review). Cochrane Database Syst Rev 2003 2 : CD003467.
90. Metman LV, Del Dotto P, LePoole K et al. Amantadine for levodopa induced dyskinesias: a 1-year follow-up study. Arch Neurol 1999 56 : 1383 1386.
91. Butzer JF, Silver DE, Sahs AL. Amantadine in Parkinson's disease: a double-blind, placebo-controlled, crossover study with long-term follow-up. Neurology 1975 25 : 603 606.
92. Katzenschlager R, Sampaio C, Costa J et al. Anticholinergics for symptomatic management of Parkinson's disease. Cochrane Database Syst Rev 2002 3 : CD003735.
93. Stacy M. Pharmacotherapy for advanced Parkinson's disease. Pharmacotherapy 2000 20 : 8 16.
94. Jankovic J. Levodopa strengths and weaknesses. Neurology 2002 58 : 19 32.
95. Deleu D, Northway MG, Hanssens Y. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease. Clin Pharmacokinet 2000 41 : 261 309.
96. Horstink M, Tolosa E, Bonuccelli U et al. Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I: early (uncomplicated) Parkinson's disease. Eur J Neurol 2006 13 : 1170 1185. (Pubitemid 44581464)
97. Kostic V, Przedborski S, Flaster E et al. Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease. Neurology 1991 41 : 202 205.
98. Grosset D, Taurah L, Burn DJ et al. A multicentre longitudinal observational study of changes in self reported health status in people with Parkinson's disease left untreated at diagnosis. J Neurol Neurosurg Psychiatry 2007 78 : 465 469.
99. Schapira AH. Treatment options in the modern management of parkinson disease. Arch Neurol 2007 64 : 1083 1088.
100. Schapira AH, Obeso J. Timing of treatment initiation in Parkinson's disease: a need for reappraisal? Ann Neurol 2006 59 : 559 562.
101. Nutt JG, Wooten GF. Clinical practice. Diagnosis and initial management of Parkinson's disease. N Engl J Med 2005 353 : 1021 1027.
102. Miyasaki JM, Martin W, Suchowersky O et al. Practice parameter: Initiation of treatment for Parkinson's disease: an evidence-based review Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2002 58 : 11 7.
103. Hauser RA, Panisset M, Abbruzzese G et al. Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease. Mov Disord 2009 24 : 541 550.